Our results demonstrate that LCD reduces inflammatory responses by inhibiting NF-κB signaling pathway activation, thereby restoring bone loss caused by SLE through coordinated effects on inflammatory cytokine networks and bone cell function. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.